Wilke Andreas, Wende Christian M, Horst Michael, Steverding Dietmar
Kardiologische Praxis Papenburg, Papenburg, Germany.
Abteilung Kardiologie, Marienkrankenhaus Papenburg, Papenburg, Germany.
Cardiol Res. 2011 Dec;2(6):298-300. doi: 10.4021/cr124w. Epub 2011 Nov 20.
Patients with prosthetic heart valves require lifelong oral anticoagulant therapy based on vitamin K antagonists. These patients may need interruption of their anticoagulant therapy if they have to undergo surgery. The clinical challenge is to identify patients who can safely undergo surgery while continuing their vitamin K antagonist treatment and those who have to take short-acting heparin as part of a bridging therapy. Here we present a case of a patient with a prosthetic mitral valve whose oral anticoagulant therapy was unnecessarily discontinued by the GP prior to an upcoming cataract surgery. As a result, the patient developed thrombosis of the prosthetic mitral valve which needed to be surgically replaced.
人工心脏瓣膜患者需要基于维生素K拮抗剂进行终身口服抗凝治疗。如果这些患者必须接受手术,可能需要中断抗凝治疗。临床面临的挑战是识别出在继续使用维生素K拮抗剂治疗的同时能够安全接受手术的患者,以及那些必须接受短效肝素作为桥接治疗一部分的患者。在此,我们呈现一例人工二尖瓣患者的病例,其口服抗凝治疗在即将进行的白内障手术前被全科医生不必要地中断。结果,该患者发生了人工二尖瓣血栓形成,需要进行手术置换。